heart iconheart icon
Skip to content

Public tender offer by Johnson & Johnson for Actelion shares

Public tender offer for all publicly held registered shares with a nominal value of CHF 0.50 each of Actelion Ltd, Switzerland

Öffentliches Kaufangebot für alle sich im Publikum befindenden Namenaktien mit einem Nennwert von je CHF 0.50 von Actelion Ltd, Schweiz

Offre publique d'acquisition sur toutes les actions nominatives d'une valeur nominale de CHF 0.50 chacune en mains du public de Actelion Ltd, Suisse

Offer Restrictions | Angebotsrestriktionen | Restrictions à l'Offre

In General | Allgemein | Généralités

The public tender offer (öffentliches Kaufangebot) described in the documents made available on this website (the Offer) is not being made and will not be made, directly or indirectly, in any country or jurisdiction in which such an Offer would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Johnson & Johnson or any of its subsidiaries to change or amend the terms or conditions of the Offer in any material way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. It is not intended to extend the Offer to any such country or jurisdiction. Any such documents relating to the Offer must neither be distributed in any such country or jurisdiction nor be sent into such country or jurisdiction, and must not be used for the purpose of soliciting the purchase of securities of Actelion Ltd by any person or entity resident or incorporated in any such country or jurisdiction.

Das in den auf dieser Website verfügbar gemachten Dokumenten beschriebene öffentliche Kaufangebot (das Angebot) wird weder direkt noch indirekt in einem Land oder einer Rechtsordnung gemacht oder gemacht werden, in welchem/welcher das Angebot widerrechtlich wäre, oder in welchem/welcher es in anderer Weise anwendbares Recht verletzen würde, oder in welchem/welcher Johnson & Johnson oder eine ihrer Tochtergesellschaften verpflichtet wäre, irgendeine wesentliche Änderung oder Anpassung der Bestimmungen oder Bedingungen, ein zusätzliches Gesuch bei staatlichen oder regulatorischen oder anderen Behörden oder zusätzliche Handlungen in Bezug auf das Angebot vorzunehmen. Es ist nicht beabsichtigt, das Angebot auf ein solches Land oder eine solche Rechtsordnung zu erstrecken. Dokumente, die in Zusammenhang mit dem Angebot stehen, dürfen weder in solchen Ländern oder Rechtsordnungen vertrieben, noch in solche Länder oder Rechtsordnungen versandt werden und dürfen zur Werbung für Käufe von Beteiligungsrechten von Actelion Ltd weder von natürlichen Personen wohnhaft noch von juristischen Personen domiziliert in solchen Ländern oder Rechtsordnungen verwendet werden.

L'Offre publique d'acquisition décrite dans les documents rendus disponibles sur ce site internet (l'Offre) n'est pas faite ni ne sera faite, directement ou indirectement, dans aucun Etat ou juridiction dans lequel|laquelle une telle Offre serait considérée comme illicite ou enfreindrait de toute autre manière les lois ou réglementations en vigueur, ou qui exigerait de la part de Johnson & Johnson ou de l'une de ses filiales, un changement significatif ou une modification significative des termes ou des conditions de l'Offre, le dépôt d'une demande en lien avec l'Offre auprès d'une quelconque autorité gouvernementale, régulatrice ou autre, ou des démarches supplémentaires en lien avec l'Offre. Il n'est pas prévu d'étendre l'Offre à de tels Etats ou juridictions. Tout document relatif à l'Offre ne doit être ni distribué ni envoyé dans de tels Etats ou juridictions et ne doit pas non plus être utilisé pour solliciter l'acquisition de titres de participation d'Actelion Ltd par toute personne ou entité domiciliée ou ayant son siège dans de tels Etats ou juridictions.

Notice to U.S. Holders

The Offer described in the documents available on this website is being made for the registered shares of Actelion Ltd, a Swiss corporation (Aktiengesellschaft) whose shares are listed on the SIX Swiss Exchange (SIX), and is subject to Swiss disclosure and procedural requirements, which are different from those of the United States of America (U.S.). The Offer is being made in the U.S. pursuant to Section 14(e) of, and Regulation 14E under, the U.S. Securities Exchange Act of 1934, as amended (the U.S. Exchange Act), subject to the exemptions provided by Rule 14d-1 and Rule 14e-5 under the U.S. Exchange Act and any exemptions from such requirements granted by the U.S. Securities and Exchange Commission (the SEC), and otherwise in accordance with the requirements of Swiss law. Accordingly, the Offer is subject to disclosure and other procedural requirements, including with respect to withdrawal rights, settlement procedures and timing of payments that are different from those applicable under U.S. domestic tender offer procedures and laws. U.S. holders of registered shares of Actelion (Actelion Shares) are encouraged to consult with their legal, financial and tax advisors regarding the Offer.

The shareholders of Actelion Ltd should review the terms and conditions of the Offer set out in the offer prospectus (the Offer Prospectus) available on the website and all other Offer documents carefully. The Offer may not be accepted before publication of the Offer Prospectus and expiration of a cooling-off period of ten (10) trading days (if not extended by the Swiss Takeover Board), which will run from the trading day immediately after the publication date of the Offer Prospectus.

According to the laws of Switzerland, Actelion Shares tendered into the Offer may generally not be withdrawn after they are tendered except under certain circumstances, in particular if a competing offer for the Actelion Shares is launched.

In accordance with the laws of Switzerland and subject to applicable regulatory requirements, Johnson & Johnson and its subsidiaries and affiliates or their respective nominees or brokers (acting as agents for Johnson & Johnson, its subsidiaries or affiliates) may from time to time after the date of the Offer Prospectus, and other than pursuant to the Offer, directly or indirectly, purchase or arrange to purchase Actelion Shares or any securities that are convertible into, exchangeable for or exercisable for Actelion Shares from shareholders of Actelion Ltd who are willing to sell their Actelion Shares outside the Offer from time to time, including purchases in the open market at prevailing prices or in private transactions at negotiated prices, and shall comply with applicable laws and regulations in Switzerland and applicable U.S. securities regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act.  Any such purchases will not be made at prices higher than the offer price or on terms more favorable than those offered pursuant to the Offer unless the offer price is increased accordingly. Any information about such purchases or arrangements to purchase will be publicly disclosed in the U.S. on Johnson & Johnson's website to the extent that such information is made public in accordance with the applicable laws and regulations of Switzerland. In addition, the financial advisor to Actelion Ltd and, subject to applicable Swiss and U.S. regulation and pursuant to exemptive relief granted by the SEC from Rule 14e-5 under the U.S. Exchange Act, the financial advisor to Johnson & Johnson and its affiliates may also engage in ordinary course trading activities in securities of Actelion Ltd, which may include purchases or arrangements to purchase such securities.

 

It may be difficult for U.S. holders to enforce their rights and any claim arising out of U.S. securities laws, since the Offeror and Actelion Ltd are located in a non-U.S. jurisdiction, and some or all of their officers and directors may be residents of a non-U.S. jurisdiction. U.S. holders may not be able to sue a non-U.S. company or its officers or directors in a U.S. or non-U.S. court for violations of the U.S. securities laws. Further, it may be difficult to compel a non-U.S. company and its affiliates to subject themselves to a U.S. court's judgment.

The receipt of cash pursuant to the Offer by a U.S. holder of Actelion Shares may be a taxable transaction for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. In addition, the receipt of shares of R&D NewCo pursuant to the demerger distribution by a U.S. holder of Actelion Shares may be taxable as a dividend for U.S. federal income tax purposes and under applicable U.S. state and local laws, as well as foreign and other tax laws. Each shareholder of Actelion Ltd is urged to consult his or her independent professional advisor immediately regarding the tax consequences of an acceptance of the Offer. Neither the SEC nor any securities commission of any State of the U.S. has (a) approved or disapproved of the Offer, (b) passed upon the merits or fairness of the Offer, or (c) passed upon the adequacy or accuracy of the disclosure in the Offer Prospectus. Any representation to the contrary is a criminal offence in the U.S.

American Depositary Shares and American Depositary Receipts

Johnson & Johnson, its subsidiaries and affiliates are aware that there are “unsponsored” American Depositary Receipt Programs concerning Actelion Shares. The Offer is not being made for American Depositary Shares representing Actelion Shares (ADSs), nor for American Depositary Receipts evidencing such ADSs (ADRs). However, the Offer is being made for the Actelion Shares that are represented by the ADSs. Holders of ADSs and ADRs are encouraged to consult with the appropriate depositary regarding the tender of Actelion Shares that are represented by ADSs. Johnson & Johnson, its subsidiaries and affiliates are unaware of whether any respective depositary will make arrangements to tender the underlying Actelion Shares into the Offer on behalf of holders of ADSs or ADRs.

Holders of ADSs may present their ADSs to the appropriate depositary for cancellation and (upon compliance with the terms of the deposit agreements relating to the “unsponsored” American Depositary Receipt Program concerning Actelion Shares, including payment of the depositary’s fees and any applicable transfer fees, taxes and governmental charges) delivery of Actelion Shares to them, in order to become shareholders of Actelion. The Offer may then be accepted in accordance with its terms for the Actelion Shares delivered to holders of ADSs upon such cancellation. Holders of ADSs should be aware, however, that in order to tender in this manner, they may need to have an account in Switzerland into which the Actelion Shares can be delivered.

 

 

Confirmation

By clicking on the "I confirm and agree" button below, you confirm and agree to each of the following:

—         that you have read and understood and that you are not subject to any of the Offer restrictions set forth above, that the communication about the Offer may lawfully be directed at and the Offer lawfully addressed to you;

—         that you are not located or resident in any jurisdiction where extension of the Offer would trigger a requirement for Johnson & Johnson or any of its affiliates or any other person to file or register an offer prospectus or any other document, or to take any other or additional action in relation to the Offer, in or by virtue of the laws of such jurisdiction;

—         that you will not copy or forward to any person any of the documents available on this website; and

—         that you understand, acknowledge and agree that failure to comply with the foregoing could result in a violation of applicable laws and|or damages to Johnson & Johnson, its affiliates and other persons.